Nigerian scientist discovers novel antibiotic for drug resistant infections

•How climate change will force new animal encounters, cause viral outbreaks, by study

A Nigeria-trained microbiologist and Associate Professor of Microbiology at the University of Texas A&M (TAMU), United States, Dr. Ugochukwu Obiakornobi Anieto, has discovered a novel antibiotic, Anietocin, an antibiotic used to treat antibiotic-resistant microbial infections.

The rapid emergence of antibiotic resistant bacteria is occurring worldwide, endangering the efficacy of antibiotics, which have hitherto transformed medicine and saved millions of lives. The antibiotic resistance crisis has been attributed to the misuse of these medications, as well as the lack of new drug development efforts.

This invention presents a new strain of Pseudomonas spp. bacteria that produces antimicrobial compounds effective against both Gram-positive and Gram-negative bacteria.

A previously unknown Pseudomonas strain has been identified and now named “Anieto”, after the TAMU inventor Anieto. The bacterium produces a novel antibiotic compound, named “Anietocin, and has been tested against several bacteria, both Gram positive and Gram negative, for growth inhibition and has so far been effective against all test bacterial species. While resistance to antibiotics is a growing global concern, this antibiotic offers the promise of alleviating the substantial health and economic burden on healthcare systems and population.

Anieto strongly believes that pharmaceutical companies can utilise this bacterium and maximise its effectiveness to treat prevailing bacterial infections in patients. His team is currently improving the chemical extraction process of this novel antibiotic and understanding the metabolomics of the bacterium to address large scale manufacturing opportunities.

There is no resistance to antibiotic observed by targeted bacterial species yet and it provides broad-spectrum antibiotic potential hunts.

Its application include: for the treatment of antibiotic resistant microbial infections; surgical and sterile environments; and point of care antibiotic prescription.

On the stage of development, the researcher said the product is undergoing laboratory trials on several bacterial species while showing consistent results.

On the patent status, Anieto said U.S. patent application is in preparation.

The drug is called “Anietocin”, after his family name, Anieto. He is a native of Umunnachi in Dunukofia Local Government Area of Anambra State.

When contacted for updates by The Guardian through his email address, Anieto said: “Sorry for the late reply, we are doing exams. ANIETOcin is from my name. We are still working on it with trials and we will have more information as soon as possible. Thank you for your kind email.”

Anieto was born and raised in Onitsha, attended Dennis Memorial Grammar School (DMGS) Onitsha and Nnamdi Azikiwe University Awka (NAU), Anambra State, where he graduated with a bachelor’s and masters degrees in Applied Microbiology and Food Microbiology. He proceeded to the United Kingdom where he was a Visiting Research Associate at the School of Medicine, Newcastle University. Thereafter he moved to the United States where he obtained his PhD in Molecular Biology at the University of North Texas, Denton. He has many years of research and teaching experience having taught in higher institutions across Nigeria and the United States. His research background is focused on bioenergy, antimicrobial resistance, food microbiology, bioinformatics etc.

He joined the College of Science of Texas A&M University McAllen Higher Education Center in August of 2018. He enjoys reading crime novels, watching documentaries and taking long walks.

ALSO, over the next 50 years, climate change could drive more than 15,000 new cases of mammals transmitting viruses to other mammals, according to a study published in Nature. It is one of the first to predict how global warming will shift wildlife habitats and increase encounters between species capable of swapping pathogens, and to quantify how many times viruses are expected to jump between species.

Many researchers say that the COVID-19 pandemic probably started when a previously unknown coronavirus passed from a wild animal to a human: a process called zoonotic transmission. A predicted rise in viruses jumping between species could trigger more outbreaks, posing a serious threat to human and animal health alike, the study warns — providing all the more reason for governments and health organisations to invest in pathogen surveillance and to improve health-care infrastructure.

The study is “a critical first step in understanding the future risk of climate and land-use change on the next pandemic”, says Kate Jones, who models interactions between ecosystems and human health at University College London.

The research predicts that much of the new virus transmission will happen when species meet for the first time as they move to cooler locales because of rising temperatures. And it projects that this will occur most often in species-rich ecosystems at high elevations, particularly areas of Africa and Asia, and in areas that are densely populated by humans, including Africa’s Sahel region, India and Indonesia. Assuming that the planet warms by no more than 2 °C above pre-industrial temperatures this century — a future predicted by some climate analyses — the number of first-time meetings between species will double by 2070, creating virus-transmission hotspots, the study says.

“This work provides us with more incontrovertible evidence that the coming decades will not only be hotter, but sicker,” says Gregory Albery, a disease ecologist at Georgetown University in Washington DC and a co-author of the study.

To make their predictions, Albery and his colleagues developed and tested models, and ran simulations over a five-year period. They combined models of virus transmission and species distribution under various climate-change scenarios, focusing on mammals because of their relevance to human health.

The team built the species-distribution model to predict where mammals would move to find more liveable habitats as the planet warms. The virus-transmission model predicts the probability of a virus jumping between species for the first time, by taking into account where species might meet as their habitats shift and how closely related they are evolutionarily (viruses are most likely to transmit between related species).

The modelling seems “technically impeccable”, says Ignacio Morales-Castilla, a global-change ecologist at the University of Alcalá, Spain, although he points out that forecasting exercises such as this sometimes need to include unrealistic assumptions. But he adds that the breadth and scope of the research and its ability to identify which parts of the world might be most at risk “clearly stand out”.

One assumption the researchers had to make was about how far and wide species would spread as the climate changes. But factors such, as whether mammals can adapt to local conditions or physically cross barriers in landscapes are difficult to predict.

Bats are projected to be involved in viral transmission regardless of these factors, the study found. Thought to be part of the origins of COVID-19, bats are known reservoirs of viruses and make up about 20 per cent of mammals. The team says that — in part because bats can fly — they are less likely to experience barriers to shifting their habitats.

Although Jones applauds the study, she urges caution when discussing its implications for human health. “Predicting the risk of viral jumps from mammals into humans is more tricky, as these spillovers take place in a complex ecological and human socio-economic environment,” she says.

COVID is spreading in deer. What does that mean for the pandemic? Many factors could reduce the risk to human health, including increased investment in health care or a virus being unable to infect humans for some reason, she adds.

But the researchers urge that there is no time to waste. Earth has already warmed by more than 1 °C above pre-industrial temperatures, and this is driving species migration and disease swapping. “It is happening and it is not preventable, even in the best climate-change scenarios,” Albery says.

Albery and one of his co-authors, Colin Carlson, a global-change biologist also at Georgetown University, say that even though some increase in disease transmission is inevitable, that is no excuse for inaction. The researchers call on governments and the international community to improve the monitoring and surveillance of wild animals and zoonotic diseases, particularly in future hotspots such as Southeast Asia. Improving health infrastructure is also essential, they say.

As people begin to prepare for and adapt to global warming, most efforts focus on activities such as halting deforestation or reinforcing sea walls. But Carlson says pandemic preparedness and disease surveillance are climate-change adaptation, too.